{
    "Trade/Device Name(s)": [
        "Access Intact PTH"
    ],
    "Submitter Information": "Beckman Coulter, Inc.",
    "510(k) Number": "K232791",
    "Predicate Device Reference 510(k) Number(s)": [
        "K061190"
    ],
    "Regulatory Class": "Class II",
    "Product Code(s)": [
        "CEW"
    ],
    "Summary Letter Date": "March 1, 2024",
    "Summary Letter Received Date": "January 22, 2024",
    "Submission Date": "January 22, 2024",
    "Regulation Number(s)": [
        "21 CFR 862.1545"
    ],
    "Regulation Name(s)": [
        "Parathyroid hormone test system"
    ],
    "Analyte Class(es)": [
        "endocrine"
    ],
    "Analyte(s)": [
        "Parathyroid hormone (PTH)",
        "Parathyrin"
    ],
    "Specimen Type(s)": [
        "Serum",
        "Plasma"
    ],
    "Specimen Container(s)": [
        "Heparin tube",
        "EDTA tube"
    ],
    "Instrument(s)/Platform(s)": [
        "DxI 9000 Access Immunoassay Analyzer",
        "Access Immunoassay Systems"
    ],
    "Method(s)/Technology(ies)": [
        "Chemiluminescent immunoassay",
        "Sandwich immunoenzymatic assay"
    ],
    "Methodologies": [
        "Immunoassay"
    ],
    "Submission Type(s)": [
        "Assay",
        "Calibrator",
        "Reagent",
        "Buffer",
        "Substrate"
    ],
    "Document Summary": "FDA 510(k) summary for Access Intact PTH sandwich immunoenzymatic chemiluminescent assay for quantitation of intact parathyroid hormone in human serum and plasma using DxI 9000 Access Immunoassay Analyzer.",
    "Indications for Use Summary": "For quantitative determination of intact parathyroid hormone (parathyrin, PTH) in human serum and plasma to aid in the differential diagnosis of hyperparathyroidism, hypoparathyroidism, or hypercalcemia of malignancy and for intraoperative use, with results used alongside other clinical data for patient management.",
    "fda_folder": "Clinical Chemistry"
}